South Korean clinics provide effective alternatives when BCG (Bacillus Calmette‑Guerin) is unavailable. These include intravesical gemcitabine, docetaxel, mitomycin C, pembrolizumab immunotherapy, and radical cystectomy. Specialist oncology centres in Seoul maintain high standards through JCI-accredited facilities and international cancer centre partnerships.
- Combination chemotherapy: gemcitabine and docetaxel provide a high-success alternative to BCG.
- Mitomycin C: an established agent used for induction and maintenance for one year.
- Systemic immunotherapy: pembrolizumab is available for patients with BCG-unresponsive carcinoma in situ.
- Surgical intervention: radical cystectomy remains the gold standard for high-risk cases.
Bookimed Expert Insight: Leading Seoul facilities like Severance Hospital maintain formal partnerships with MD Anderson and Johns Hopkins. This gives patients access to the same evidence-based alternatives used in top American cancer centres. When BCG is scarce, these clinics rely on high-volume robotic surgery expertise to manage complex cases.
Patient Consensus: Patients value the quick switch to alternative drugs like gemcitabine at modern Korean hospitals. The coordination between specialists keeps treatment on schedule even during global supply shortages.